Clove for Dental Pain and Oral Health

Clove's use against dental pain is one of the oldest documented medicinal applications of any plant. Han Dynasty Chinese officials chewed cloves to mask breath odor and ease toothache more than two thousand years ago. Persian and Arab physicians of the medieval period recorded clove as their first-line dental remedy. Modern dentistry has not abandoned this tradition — it codified it. Zinc oxide eugenol (ZOE) cement, formulated by mixing zinc oxide powder with clove-derived eugenol oil, is still one of the most widely used temporary restorative materials in dental practice worldwide, valued for its sedative effect on the dental pulp and its mild antimicrobial activity. In 2006, the Alqareer randomized clinical trial in Kuwait formally demonstrated what folk practice had known for two millennia: a topical clove preparation produces analgesia non-inferior to a 20% benzocaine gel for needle-stick pain. This deep-dive walks through the molecular mechanism (TRP channel desensitization), the modern ZOE chemistry, the clinical trials in toothache and periodontal disease, and the practical home-use protocols.


Table of Contents

  1. The Ancient Dental Remedy — Han Dynasty to Modern Times
  2. How Eugenol Numbs Pain — TRPV1 and TRPA1 Channel Modulation
  3. Zinc Oxide Eugenol (ZOE) — The Standard Temporary Dental Material
  4. The Alqareer 2006 Trial — Clove vs Benzocaine
  5. Gingivitis and Periodontitis — Eugenol Against Oral Pathogens
  6. Eugenol Mouthwash and Oral Rinse Formulations
  7. Dry Socket (Alveolar Osteitis) — Eugenol Dressings
  8. Endodontic Applications — Root Canal Sealers
  9. Practical Home Use — Whole Clove, Powder, and Diluted Oil
  10. Cautions and Adverse Effects
  11. Key Research Papers
  12. Connections

The Ancient Dental Remedy — Han Dynasty to Modern Times

The earliest documented use of clove for dental pain comes from the Han Dynasty court of China, where the spice was imported along the Maritime Silk Road from the Maluku Islands (the "Spice Islands" of what is now eastern Indonesia). Han court officials addressing the emperor were required to chew cloves before speaking, ostensibly to freshen the breath but with the side effect of numbing minor toothache. The practice is recorded in materia medica texts dating to the second century BCE.

Avicenna's 11th-century Canon of Medicine — the standard medical textbook of the Islamic Golden Age and, after Latin translation, of medieval European universities for nearly six centuries — recommended clove specifically for "pain of the teeth and gums." The recommendation appears in nearly every European herbal from Culpeper's 1653 Complete Herbal onward. Folk preparations included chewing a whole dried bud held against the affected tooth, applying clove powder mixed with honey or oil, or biting on a cotton wad soaked in clove water.

When 19th-century chemistry isolated eugenol as the principal active constituent (Bonastre, 1827; Ettling, 1834), the way was open to formal pharmaceutical use. By the early 20th century, zinc oxide eugenol cement was a standard dental material, and eugenol itself was listed in the United States Pharmacopeia as a topical dental anesthetic. The 2006 Alqareer trial closed the loop by formally demonstrating clinical equivalence to a benchmark synthetic anesthetic.

Back to Table of Contents


How Eugenol Numbs Pain — TRPV1 and TRPA1 Channel Modulation

The molecular pharmacology of eugenol's topical anesthetic effect was worked out in the 2000s. Eugenol is a partial agonist at two ion channels expressed on peripheral nociceptive nerve endings:

In parallel with TRP channel desensitization, eugenol at higher local concentrations directly inhibits voltage-gated sodium channels on the same nerve endings, producing local-anesthetic-like blockade of action potential propagation. This is a "frequency-dependent" block similar to that of lidocaine, blocking high-firing-rate nociceptive fibers preferentially over low-firing-rate touch fibers.

The combination of TRP desensitization and sodium channel block produces an analgesic effect that begins within 60–90 seconds of topical application and lasts 15–30 minutes per application. Onset is faster than most synthetic topical anesthetics; duration is shorter than lidocaine, which is why eugenol is favored for brief procedures or as a stop-gap before definitive dental care.

Back to Table of Contents


Zinc Oxide Eugenol (ZOE) — The Standard Temporary Dental Material

Zinc oxide eugenol cement is a two-component dental material that, when mixed, forms a hard, set, but not permanently bonded restorative material with analgesic and antimicrobial properties. Mixing zinc oxide powder with eugenol oil produces a chelation reaction that generates zinc eugenolate crystals embedded in a matrix of unreacted zinc oxide. The set material has the following dental-clinical properties:

Reinforced ZOE formulations (with added polymethylmethacrylate or alumina fillers) have improved mechanical strength and are used as intermediate restorative materials for temporary crowns and as root canal sealers (see Endodontic Applications below).

Back to Table of Contents


The Alqareer 2006 Trial — Clove vs Benzocaine

The Alqareer, Alyahya, and Andersson 2006 randomized trial published in the Journal of Dentistry is the most-cited modern clinical evidence for clove as a topical dental anesthetic. The trial design was rigorous for its question:

Results: the clove gel and the 20% benzocaine gel produced statistically indistinguishable VAS pain scores, both significantly lower than the corresponding placebo gels. The conclusion, stated cautiously in the paper, was that clove preparations “may have a use in dentistry as a topical agent prior to needle insertion.”

The trial does not claim eugenol is equivalent to a deep injected lidocaine block for major dental procedures — it is a topical agent for surface analgesia only. But for the specific clinical question of pre-injection topical numbing, a homemade clove preparation matched a commercial benchmark, with potentially better safety than benzocaine (which has a small but real risk of methemoglobinemia in infants and small children).

Back to Table of Contents


Gingivitis and Periodontitis — Eugenol Against Oral Pathogens

The clinical evidence for clove and eugenol in inflammatory gum disease (gingivitis, periodontitis) is more limited than the topical anesthesia data but consistent in direction. Several mechanisms appear to be operating in parallel:

  1. Direct antimicrobial activity against periodontal pathogens — in vitro studies show eugenol inhibits the major periodontal pathogens at minimum inhibitory concentrations (MIC) of 0.25–2 mg/mL. Sensitive species include Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola (the "red complex" of severe periodontitis), and Fusobacterium nucleatum. The membrane-disrupting mechanism applies equally to these Gram-negative anaerobes as to other bacteria.
  2. Anti-inflammatory effect on the gingival epithelium — eugenol downregulates production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) by gingival fibroblasts exposed to lipopolysaccharide (LPS) endotoxin from periodontal pathogens. The effect appears to be mediated by partial inhibition of the NF-κB transcription factor pathway.
  3. Antioxidant effect on the periodontal pocket — periodontal inflammation produces large quantities of reactive oxygen species from neutrophils. Eugenol's phenolic structure quenches these reactive species and limits collateral tissue damage to the gingival connective tissue and alveolar bone.

The Hashemipour 2013 trial in the Journal of Periodontology tested a 2% clove oil topical gel as an adjunct to standard scaling and root planing in patients with chronic periodontitis. The clove arm showed greater reductions in gingival bleeding index and probing depth at six weeks compared with the scaling-only control, though the effect size was modest. Several smaller trials of clove-containing mouthwashes (often combined with other plant extracts like neem and tea tree) have shown similar gingivitis-reduction effects in 4–12 week trials.

Back to Table of Contents


Eugenol Mouthwash and Oral Rinse Formulations

Clove-based oral rinses fall into several categories with different clinical positioning:

A meta-analysis of herbal mouthwash trials including clove-containing products (multiple authors, 2014–2020) finds modest but real reductions in plaque index and gingival inflammation index compared with placebo rinses, with effect sizes generally smaller than chlorhexidine 0.12% (the dental-clinic gold-standard antiseptic mouthwash) but with better tolerability and no staining of teeth.

Back to Table of Contents


Dry Socket (Alveolar Osteitis) — Eugenol Dressings

Dry socket (alveolar osteitis) is a painful complication of tooth extraction, particularly mandibular third molar extraction, in which the blood clot that normally fills the extraction socket dislodges or fails to form, leaving exposed bone. It occurs in approximately 2–5% of routine extractions and 25–30% of impacted third molar extractions. The pain is severe and typically begins 2–4 days after extraction.

The classical treatment is a medicated dressing placed into the empty socket. The historical and still widely used preparation is Alvogyl (also called Alveogyl), a paste containing eugenol, butamben (a local anesthetic), and iodoform (an antimicrobial). The eugenol provides immediate analgesia by desensitizing the exposed nociceptors on the bone surface; the butamben provides additional sodium-channel blockade; the iodoform provides slow-release antimicrobial activity against contaminating oral flora.

Plain zinc oxide eugenol cement is also commonly used as a dry socket dressing, particularly when iodoform sensitivity is suspected. The dressing is typically replaced every 24–48 hours for 3–5 days until granulation tissue covers the exposed bone. Newer alternatives include chlorhexidine-impregnated gels and platelet-rich fibrin, but eugenol-based dressings remain the most widely used worldwide for cost and efficacy reasons.

Back to Table of Contents


Endodontic Applications — Root Canal Sealers

Endodontic (root canal) treatment requires obturating the cleaned and shaped root canal with a filling material that seals it against bacterial re-entry from the oral cavity and from the periapical tissues. The classical obturation technique uses gutta-percha cones as the core material together with a sealer cement that fills micro-irregularities between the gutta-percha and the canal wall. Several major sealer formulations are eugenol-based:

Eugenol-based sealers have been the workhorse of endodontic practice for the better part of a century. Newer alternatives (calcium hydroxide-based, bioceramic, methacrylate resin sealers) have specific niche advantages, but eugenol-based sealers retain widespread use because of their proven long-term clinical performance, antimicrobial properties, dimensional stability, and ease of removal if retreatment becomes necessary. The trade-off is the same as with ZOE temporary restorations — eugenol inhibits the polymerization of methacrylate-based bonding agents and composite resins, so coronal restorations placed on top of eugenol-sealed root canals must use a non-resin material as the immediate coronal seal.

Back to Table of Contents


Practical Home Use — Whole Clove, Powder, and Diluted Oil

For occasional home use of clove against minor dental pain — a flare-up before a scheduled dentist visit, a lost filling needing temporary coverage, mild gum inflammation — several preparations are widely available and safe when used within recommended limits:

Home use of clove is a stop-gap, not a substitute for definitive dental care. Untreated dental caries, cracked teeth, or abscesses progress regardless of symptom control. If pain persists more than 48 hours, or is associated with facial swelling, fever, or systemic symptoms, urgent dental evaluation is required — an untreated dental abscess can progress to cellulitis or in rare cases life-threatening Ludwig's angina.

Back to Table of Contents


Cautions and Adverse Effects

Back to Table of Contents


Key Research Papers

  1. Alqareer A, Alyahya A, Andersson L (2006). The effect of clove and benzocaine versus placebo as topical anesthetics. Journal of Dentistry. — PubMed
  2. Markowitz K, Moynihan M, Liu M, Kim S (1992). Biologic properties of eugenol and zinc oxide-eugenol. A clinically oriented review. Oral Surgery Oral Medicine Oral Pathology. — PubMed
  3. Hashemipour MA, Lotfi S, Torabi M (2013). Anti-inflammatory and antimicrobial effects of clove and its constituents on periodontal pathogens. Journal of Periodontology. — PubMed
  4. Pramod K, Ansari SH, Ali J (2010). Eugenol: a natural compound with versatile pharmacological actions. Natural Product Communications. — PubMed
  5. Yang BH et al. (2003). Eugenol inhibits the action potentials in rat trigeminal ganglion neurons. Pain. — PubMed
  6. Park CK et al. (2009). Eugenol inhibits sodium currents in dental afferent neurons. Journal of Dental Research. — PubMed
  7. Bhat SP et al. (2014). Clove oil as a haemostatic agent in dental practice: in vitro study. Journal of Indian Society of Periodontology. — PubMed
  8. Cai L, Wu CD (1996). Compounds from Syzygium aromaticum possessing growth inhibitory activity against oral pathogens. Journal of Natural Products. — PubMed
  9. Khan ST et al. (2009). Antimicrobial activity of Syzygium aromaticum extracts against oral bacteria. Journal of Dentistry. — PubMed
  10. Chaieb K et al. (2007). The chemical composition and biological activity of clove essential oil. Phytotherapy Research. — PubMed
  11. Lane BW, Ellenhorn MJ, Hulbert TV, McCarron M (1991). Clove oil ingestion in an infant. Human & Experimental Toxicology. — PubMed
  12. Janes SE, Price CS, Thomas D (2005). Essential oil poisoning: N-acetylcysteine for eugenol-induced hepatic failure. European Journal of Pediatrics. — PubMed

PubMed Topic Searches

Back to Table of Contents


Connections

Back to Table of Contents